Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas

Journal of Veterinary Internal Medicine

Volumn 22, Issue 6, 2008, Pages 1373-1379

  Elmslie, R E ^a   Glawe, P ^a   Dow, Steven W ^b  

^a Animal Cancer Center ^*

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Angiogenesis; Cancer; Chemotherapy; Cyclooxygenase

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; PIROXICAM;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; RETROSPECTIVE STUDY; SARCOMA; SOFT TISSUE TUMOR; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOG DISEASES; DOGS; NEOPLASM RECURRENCE, LOCAL; PIROXICAM; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 57149114371     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0179.x     Document Type: Article

References (46)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
2. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
3. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274.
4. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7:427-436.
5. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
6. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206.
7. Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004;27:599-605.
8. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-3061.
9. Lam T, Hetherington JW, Greenman J, et al. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 2006;17:113-121.
10. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-459.
11. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-12922.
12. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496-507.
13. Kamat AA, Kim TJ, Landen CN Jr., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-288.
14. Salem ML, Kadima AN, El-Naggar SA, et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: Creation of a beneficial host microenvironment involving type I IFNs and myeloid cells (1997). J Immunother 2007;30:40-53.
15. Matar P, Rozados VR, Gonzalez AD, et al. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 2000;36:1060-1066.
16. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-648.
17. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-192.
18. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19-27.
19. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-631.
20. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
21. Yaqub S, Henjum K, Mahic M, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2007;57:813-821.
22. Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/ prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-5220.
23. Baratelli F, Lin Y, Zhu L, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005;175:1483-1490.
24. Mahic M, Yaqub S, Johansson CC, et al. FOXP3+ CD4+ CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006;177:246-254.
25. Buckstein R, Kerbel RS, Shaked Y, et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-5198.
26. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: A pilot study. Cancer Chemother Pharmacol 2003;52:377-382.
27. Kesari S, Schiff D, Doherty L, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007;9:354-363.
28. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.
29. Knapp DW, Glickman NW, Mohammed SI, et al. Antitumor effects of piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer. Adv Exp Med Biol 2002;507:377-380.
30. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
31. Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801-805.
32. Greene SN, Lucroy MD, Greenberg CB, et al. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2007;231:1056-1060.
33. Lana S, U'Ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007;21:764-769.
34. Thrall DE, Gillette EL. Soft-tissue sarcomas. Semin Vet Med Surg (Small Anim) 1995;10:173-179.
35. Mauldin GN. Soft tissue sarcomas. Vet Clin North Am Small Anim Pract 1997;27:139-148.
36. Withrow SJ. Soft tissue sarcomas. Vet Q 1998;20(Suppl 1):S16-S17.
37. Forrest LJ, Chun R, Adams WM, et al. Postoperative radiotherapy for canine soft tissue sarcoma. J Vet Intern Med 2000;14:578-582.
38. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000;18:781-792.
39. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720-728.
40. Lamerato-Kozicki AR, Helm KM, Jubala CM, et al. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol 2006;34:870-878.
41. Maraveyas A, Lam T, Hetherington JW, et al. Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer 2005;92:1588-1590.
42. Emmenegger U, Shaked Y, Man S, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther 2007;6:2280-2289.
43. Biller BJ, Elmslie RE, Burnett RC, et al. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 2007;116:69-78.
44. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
45. Charney SC, Bergman PJ, Hohenhaus AE, et al. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). J Am Vet Med Assoc 2003;222:1388-1393.
46. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65:7045-7051.